Welcome to our dedicated page for Retractable Tech news (Ticker: RVP), a resource for investors and traders seeking the latest updates and insights on Retractable Tech stock.
Retractable Technologies, Inc. reports developments tied to its safety medical products business, including VanishPoint® syringes, blood collection and IV catheter products, Patient Safe® syringes, and EasyPoint® retractable needles. The company manufactures and markets devices designed to reduce needlestick injuries, product reuse, and catheter-related contamination risks, with distribution through specialty and general line medical distributors.
Recurring news themes for RVP include operating results, domestic and international sales trends, product mix shifts involving EasyPoint® needles, tariff exposure on products imported from China, and changes in manufacturing activity as the company expands domestic production where practical. Updates also cover workforce reductions, product designations, and dividends on Series II and Series III Class B Convertible Preferred Stock.
Retractable Technologies, Inc. (RVP) reported significant growth in 2020, with operational income rising to approximately $24 million from $3 million in 2019. Revenues surged by 74%, driven primarily by demand for syringes due to COVID-19 vaccinations, with the U.S. government accounting for 39% of total revenues. Domestic sales increased by 131%, while international sales saw a decline of 19%. Operating expenses rose by 16%. New contracts with the U.S. government totaled approximately $138 million, supporting future production expansions. Cash flow from operations improved significantly to $19 million.
Retractable Technologies, Inc. (NYSE American: RVP) declared dividends for its Series I Class B and Series II Class B Convertible Preferred Stock. The dividends total $10,041 for Series I and $39,050 for Series II, equating to $0.125 and $0.25 per share, respectively. The accrual period spans from October 1, 2020, to the date of conversion or December 31, 2020. Payments are scheduled for January 29, 2021, with a record date of January 19, 2021, for Series II stockholders. The company specializes in safety medical products aimed at reducing needlestick injuries and infection risks.